| 卜智斌 曹强 王勇 赵渭东 宋少伟 李晓辉.新辅助化疗后保乳手术治疗三阴性乳腺癌的临床疗效分析[J].,2016,16(30):5930-5932 |
| 新辅助化疗后保乳手术治疗三阴性乳腺癌的临床疗效分析 |
| Analysis of the Clinical Efficacy of Breast-conserving Surgeryafter Neo-adjuvant Chemotherapy in the Treatmentof Triple-negative Breast Cancer |
| |
| DOI： |
| 中文关键词: 三阴性乳腺癌 新辅助化疗 AC-T TAC 保乳手术 |
| 英文关键词: Triple-negative breast cancer Neo-adjuvant chemotherapy AC-T TAC Breast-conserving surgery |
| 基金项目: |
|
| 摘要点击次数: 690 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨不同方案新辅助化疗后行保乳手术治疗三阴性乳腺癌的临床疗效及安全性。方法：收集2006 年1 月至2015 年6
月于我院确诊的可手术三阴性乳腺癌患者90 例作为研究对象，按照随机数字表法分为观察组及对照组各45 例。观察组患者在
保乳手术前给予AC-T方案进行新辅助化疗，对照组患者在保乳手术前给予TAC方案进行新辅助化疗。观察并比较两组患者治
疗效果、化疗相关不良反应发生情况、术后并发症发生情况以及生活质量的改善情况。结果：观察组总有效率为82.22%，对照组为
73.33%；观察组控制率为95.56%，对照组为91.11%，两组总有效率及控制率比较差异无统计学意义(P>0.05)；观察组患者中性粒
细胞减少、胃肠道不良反应及口腔溃疡发生率均低于对照组(P<0.05)，而两组脱发情况比较差异无统计学意义(P>0.05)。两组术后
并发症发生率分别为6.67%及11.11%，组间比较差异无统计学意义(P>0.05)。观察组患者术后生活质量改善总有效率为86.67%，
对照组总有效率为82.22%，两组相比差异无统计学意义(P>0.05)。结论：在保乳手术前采用AC-T 序贯化疗方案进行新辅助化疗
治疗三阴性乳腺癌与TAC方案疗效相当，但不良反应明显减少，值得临床推广应用。 |
| 英文摘要: |
| Objective:To explore the efficacy of different neo-adjuvant methods before breast-conserving surgery in the treatment
of patients with triple-negative breast cancer.Methods:90 patients with triple-negative breast cancer admitted in our hospital from Jan.
2006 to June 2015 were selected and randomly divided into the observation group and control group with 45 cases in each group. AC-T
neo-adjuvant chemotherapy was given to the observation group, and TAC chemotherapy was given to the control group before surgery.
Then the efficacy, adverse reactions, complications after surgery and improvement of quality of life in two groups were compared.Results:The total efficacy of observation group and control group were 82.22%, 73.33%. The disease control rate of observation group
and control group were 95.56%, 91.11%. There was no significant difference between two groups (P>0.05). The incidence rates of
neutropenia, gastrointestinal adverse reaction and mouth ulcers of observation roup were obviously lower than those of the control group
(P<0.05). The complication rate of two groups were 6.67% and 11.11% respectively with no difference between two groups (P>0.05).
The improvement rate of quality of life was 86.67% and 82.22% in the observation group and control group respectively, which had no
statistically significance (P>0.05).Conclusion:AC-T neo-adjuvant chemotherapy before breast-conserving surgery had equal efficacy as
TAC chemotherapy in the treatment of patients with triple-negative breast cancer, but the adverse reaction of AC-T was obviously less,
which was worth clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
